Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Molecular Testing in Metastatic mNSCLC

July 1st 2021

Panelists reflect on barriers to obtaining tissue biopsies in patients with EGFR-mutated metastatic NSCLC and share insights into the importance of making treatment decisions based on molecular testing results.

Mason Spotlights on Surgical Implications of New Lung Cancer Developments

June 30th 2021

David P. Mason, MD, discusses new neoadjuvant and adjuvant developments in the treatment of patients with non–small cell lung cancer, as well as what those data mean from a surgical perspective.

Frontline I-O Monotherapy Versus Combination Therapy for PD-L1+ Stage IV NSCLC

June 30th 2021

Drs Roy S. Herbst and Sandip P. Patel comment on patient candidacy for immunotherapy as monotherapy to treat PD-L1+ metastatic non–small cell lung cancer versus chemoimmunotherapy.

Lower Incidence of Brain Metastases Observed With Early Detection Screening in Lung Cancer

June 30th 2021

Early detection of primary lung cancer using low-dose computed tomography screening was associated with a lower risk of brain metastases after PLC diagnosis vs other methods

Frontline Treatment of PD-L1+ Stage IV NSCLC: Cemiplimab

June 30th 2021

Roy S. Herbst, MD, PhD, of Yale Cancer Center, highlights treatment advances in stage IV non–small cell lung cancer, including cemiplimab as frontline monotherapy based on EMPOWER-Lung 1.

Targeted Therapy Paradigm Grows in NSCLC, While Overcoming Resistance Represents Next Hurdle

June 29th 2021

The field of targeted therapy for patients with non–small cell lung cancer has grown exponentially in recent years, with inhibitors for RET, MET exon 14 skipping, and KRAS G12C mutations transforming the paradigm.

Galinpepimut-S Plus Nivolumab Shows Promising Preliminary Benefit in Mesothelioma

June 28th 2021

The combination of the targeted cancer vaccine galinpepimut-S plus nivolumab resulted in a median overall survival of 35.4 weeks in patients with macroscopic deposits of malignant pleural mesothelioma who had received treatment for at least 1 month.

Circling the Latest With ctDNA in Lung Cancer

June 28th 2021

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, discuss the utility with circulating tumor DNA, intriguing data of which were presented during the 2021 ASCO Annual Meeting.

ASCO 2021 Updates With Neoadjuvant Immunotherapy in NSCLC

June 28th 2021

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, cover the latest results with neoadjuvant immunotherapy strategies that were highlighted at the 2021 ASCO Annual Meeting.

What’s Next in HER2+ and Exon 19 Deletions in NSCLC?

June 28th 2021

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, recap the 2021 ASCO Annual Meeting and focus on data presented in patients with non–small cell lung cancer that is HER2 positive or harbors an exon 19 deletion.

Enthusiasm With EGFR Exon 20+ in NSCLC

June 28th 2021

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, highlight the intriguing data in the realm of EGFR exon 21 insertion mutations in non–small cell lung cancer presented during the 2021 ASCO Annual Meeting.

Kicking Off With KRAS in NSCLC

June 28th 2021

OncLive’s third episode of Thoracic Night Live, a program devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year, focuses on findings presented at the 2021 ASCO Annual Meeting.

Lopes Shines a Light on the Explosion of Targeted Therapies in Lung Cancer Treatment Arsenal

June 26th 2021

Gilberto Lopes, MD, discusses the latest developments made in the treatment of patients with non–small cell lung cancer whose tumors harbor genetic alterations and the clinical implications of recent regulatory approvals.

FDA Grants Breakthrough Therapy Designation to Adagrasib for KRAS G12C–Mutated NSCLC

June 25th 2021

The FDA has granted a breakthrough therapy designation to adagrasib for use as a potential therapeutic option for patients with KRAS G12C–mutated non–small cell lung cancer following previous systemic therapy.

Olaparib Approved in China for BRCA+ Metastatic Castration-Resistant Prostate Cancer

June 24th 2021

The Chinese National Medical Products Administration has granted conditional approval to olaparib for use as a monotherapy in the treatment in adult patients with germline or somatic BRCA-mutated, metastatic castration-resistant prostate cancer who have progressed after previous treatment that included a new hormonal agent like abiraterone acetate or enzalutamide.

Dr. Schram on the Results of the Phase 1/2 eNRGy Trial in NRG1+ Solid Tumors

June 24th 2021

Alison Schram, MD, discusses the results of the phase 1/2 eNRGy trial, which were presented during the 2021 ASCO Annual Meeting, in NRG1 fusion–positive solid tumors.

Frontline Domvanalimab-Based Combos Elicit Encouraging ORRs in PD-L1–High NSCLC

June 24th 2021

The anti-TIGIT agent domvanalimab in combination with zimberelimab with or without etrumadenant demonstrated promising objective response rates when given as a first-line treatment in patients with metastatic non–small cell lung cancer who have a PD-L1 expression of 50% or higher.

Treatment of Unresectable EGFR-Mutated NSCLC

June 24th 2021

Key opinion leaders in lung cancer have a lively discussion on the challenges associated with making treatment decisions for patients with unresected stage III EGFR-mutated NSCLC.

Treatment Approaches After Adjuvant Osimertinib

June 24th 2021

A panel of thought leaders in the management of NSCLC review best practices for monitoring patients and making treatment decisions after adjuvant osimertinib.

Dr. Malhotra on the Safety Profile of Plinabulin/Nivolumab/Ipilimumab in Relapsed SCLC

June 23rd 2021

Jyoti Malhotra, MD, MPH, discusses the safety profile of plinabulin in combination with nivolumab and ipilimumab in relapsed/refractory small cell lung cancer.